The oral GLP-1 race has its first scoreboard, and it is not close. Novo Nordisk’s Wegovy pill brought in $354 million (DKK 2.26 billion) in Q1 on approximately 1.3 million prescriptions, nearly doubling the consensus estimate of DKK 1.16 billion. Cumulative prescriptions since the January 5 launch have surpassed 2 million. Weekly prescriptions exceeded 200,000 by mid-April. Novo called it the “strongest-ever GLP-1 volume launch in the United States.” Wegovy injectable grew 12% with no cannibalization from the pill—CEO Mike Doustdar told CNBC it is “having not cannibalizations, but a synergetic effect.” The broader obesity care category grew 22% at constant currency. Doustdar said the Wegovy brand now accounts for 65% of new U.S. prescriptions in the obesity category. Novo raised its full-year 2026 guidance, narrowing the expected decline from 5-to-13% to 4-to-12%. NVO shares rose approximately 7% in Copenhagen. Foundayo, which launched three months later in April, logged 3,707 prescriptions in its second full week and has not yet contributed revenue. The early gap is undeniable. But Lilly CEO David Ricks has said the launch would take “quarters, not days,” and RBC’s Huynh said Weeks 8 through 12 are the earliest window for true assessment.
Top Story: Novo Delivers the Strongest GLP-1 Pill Launch in History
What Happened: Novo Nordisk reported Q1 2026 results on May 6 that beat expectations across the board, driven by the Wegovy pill’s stronger-than-expected commercial debut.
The Q1 Numbers
Total revenue: DKK 96.8 billion ($15.2 billion), up 32% year-over-year. Adjusted operating profit was DKK 32.9 billion. Adjusted sales and operating income beat expectations by 1% and 14% respectively, per Jefferies. NVO shares rose approximately 7% in Copenhagen.
The Wegovy Pill: Nearly Double the Consensus
Q1 revenue for the Wegovy pill was DKK 2.26 billion (approximately $354 million). The Jefferies consensus estimate was DKK 1.16 billion. The beat was nearly 100%—a magnitude that rarely occurs in large-cap pharma earnings.
The volume numbers tell the story. Novo reported approximately 1.3 million prescriptions in Q1 for the Wegovy pill. Cumulative prescriptions since the January 5 launch have surpassed 2 million. By the week ending April 17, weekly prescriptions exceeded 200,000. Novo called it the “strongest-ever GLP-1 volume launch in the United States.” First launches outside the U.S. are expected in H2 2026, pending regulatory approvals.
Jefferies analyst Michael Leuchten noted the beat magnitude as exceptional. A near-100% revenue beat in the first reporting quarter of a new product launch signals that the market systematically underestimated the speed and scale of patient adoption.
Injectable Wegovy: No Cannibalization
One of the key investor concerns heading into this quarter was whether the Wegovy pill would pull patients off the injectable. The answer is definitive: it is not.
Wegovy injectable revenue was DKK 18.2 billion, up 12% year-over-year. It came in slightly below LSEG expectations, but the growth was positive. CEO Doustdar was explicit on the cannibalization question, telling CNBC: “It’s having not cannibalizations, but a synergetic effect.”
This is the best outcome Novo could have hoped for. The pill is additive to the franchise, not substitutive. Patients choosing the pill are predominantly new GLP-1 patients—people who would not have started injectable therapy due to needle aversion, lifestyle incompatibility, or cost concerns—rather than existing injectable users switching formats. The pill is expanding the total addressable market rather than reshuffling patients within the existing franchise.
Ozempic: Down but Above Expectations
Ozempic revenue was DKK 27.8 billion, down 8% year-over-year but above analyst expectations per LSEG. The decline reflects competitive pressure in the diabetes market, including Mounjaro’s continued growth. Novo launched oral Ozempic (the Rybelsus rebrand) in 70,000-plus U.S. pharmacies on May 4, which will contribute to Q2 results.
The Obesity Market Share Number That Should Worry Lilly
Doustdar told CNBC that the Wegovy brand now accounts for 65% of new U.S. prescriptions in the obesity category. That market share figure encompasses both the injectable and the pill, but it demonstrates the commanding position Novo holds in new patient acquisition for weight management.
For Lilly, the implication is direct. Foundayo launched into a market where Novo is capturing nearly two-thirds of new prescriptions. Breaking through that level of market share dominance requires either a fundamentally superior product profile, a substantially lower price point, or a distribution advantage that Novo cannot match. Foundayo has a convenience advantage (no fasting requirement) and a lower self-pay entry price ($149 versus $249 on Novo’s 12-month subscription plan). Whether those differentiators are sufficient to close a 65% market share gap will be determined over the next two quarters. The challenge is that market share dominance tends to be self-reinforcing: more prescriptions generate more physician familiarity, more patient word-of-mouth, and more telehealth platform integration, all of which drive additional prescriptions.
The Broader Obesity Franchise Is Growing
Obesity care adjusted constant currency sales grew 22%. The growth is being driven by multiple products simultaneously: injectable Wegovy, the Wegovy pill, Wegovy HD (injectable 7.2 mg, approved March, launched April 7 with 20.7% mean weight loss in the STEP UP trial), and the subscription pricing model through telehealth partners.
Updated 2026 Guidance
Novo raised its full-year guidance, narrowing the expected adjusted sales and operating profit decline from 5-to-13% to 4-to-12%. The improvement was driven by the Wegovy pill’s stronger-than-expected momentum. If the pill continues to ramp in Q2 and Q3, additional guidance raises are likely.
Pipeline: Next-Generation Obesity Candidate Enters Phase 3
During Q1, Novo initiated the AMAZE Phase 3 program for zenagamtide (amycretin), a dual GLP-1/amylin agonist that represents Novo’s next-generation obesity candidate beyond semaglutide. Amylin is a hormone that works synergistically with GLP-1 to reduce appetite and food intake through complementary mechanisms in the brain. If the Phase 3 data demonstrate superior weight loss to semaglutide alone, zenagamtide would give Novo a mechanism-level advantage that current GLP-1 competitors cannot match—a next-generation product waiting in the pipeline while the current generation is still ramping commercially.
Novo also confirmed the Awiqli (once-weekly insulin) U.S. launch is expected in H2 2026. And Wegovy HD (injectable semaglutide 7.2 mg), which received FDA approval in March and launched in the U.S. on April 7, demonstrated 20.7% mean weight loss in the STEP UP trial—a higher-dose option for patients seeking maximum efficacy from the injectable format. Initial TRx data for Wegovy HD will be an important metric in Q2 reporting.
Our Pro brief analyzes why the Wegovy pill launch changes the competitive math, what the “synergetic effect” means for the total GLP-1 franchise, and how dose titration over the coming quarters will accelerate revenue per prescription beyond the starter-dose-heavy Q1 mix. [Details below.]
What to Watch
The weekly TRx trajectory for the Wegovy pill will determine whether the 200,000-plus weekly run rate is sustainable or whether it plateaus. Dose titration is the key revenue variable: as the 1.3 million Q1 patients move from starter doses to maintenance doses over the next two to three quarters, revenue per prescription should increase substantially. Foundayo’s trajectory over Weeks 3 through 8 will determine whether Lilly can close the early gap or whether Novo’s first-mover advantage creates a self-reinforcing cycle of market dominance. And the Wegovy HD launch (injectable 7.2 mg) adds another growth vector that could further extend Novo’s franchise lead.
The Early Oral GLP-1 Competitive Gap
The first quarter of head-to-head oral GLP-1 competition produced a lopsided result.
Novo’s Wegovy pill launched January 5 and generated $354 million on 2 million-plus cumulative prescriptions, with weekly volume exceeding 200,000 by mid-April. Lilly’s Foundayo launched April 6 and has reached approximately 20,000 patients, with 3,707 prescriptions in its second full week. Foundayo has not yet contributed revenue.
The scale of the gap reflects three fundamental dynamics.
First-mover advantage. Novo had three months of market development before Foundayo’s first prescription was written. Physician familiarity, telehealth partnerships, and patient awareness all compound over time. By the time Foundayo launched, Novo’s oral Wegovy was already an established presence in the prescribing workflow of thousands of physicians and telehealth platforms.
Brand extension versus new brand. Oral Wegovy extended the most recognized weight-loss drug brand in the world into a new format. Foundayo is a completely new brand, new molecule, and new mechanism. The effort required to build awareness from zero is fundamentally greater than extending awareness from an existing brand.
Market share momentum. With Wegovy capturing 65% of new obesity prescriptions, the competitive environment favors the incumbent. Foundayo must convince physicians and patients to choose a newer, less familiar option over a brand that is already working for millions of patients.
Why the Gap Could Narrow
Despite the lopsided early numbers, the competitive dynamics are not permanently settled.
Foundayo’s $149 self-pay entry price is lower than oral Wegovy’s comparable pricing tiers. For price-sensitive patients and the telehealth platforms that serve them, cost matters.
Foundayo’s no-fasting convenience is a genuine clinical differentiator. Oral Wegovy requires a 30-minute empty-stomach window. Foundayo can be taken any time with no food or water restrictions. As physician and patient awareness of this difference grows, it may attract patients who find the fasting requirement burdensome.
The ACHIEVE-4 data gives Foundayo a clinical profile that oral Wegovy does not have: cardiovascular safety confirmation and a mortality signal versus insulin in the largest Foundayo diabetes trial. The type 2 diabetes filing (late Q2 under CNPV) would give Foundayo an indication that oral Wegovy does not carry, opening an additional 37 million potential patients.
And Lilly CEO Ricks has explicitly said the launch will take “quarters, not days.” RBC’s Huynh said Weeks 8 through 12 are the earliest window for meaningful assessment. Foundayo is in approximately Week 3. The current gap may reflect the inherent disadvantage of launching three months later rather than a permanent competitive deficit.
Our Pro brief includes the full competitive scorecard across pricing, dosing, market share, revenue, and clinical differentiation, with analysis of what Foundayo needs to do over the next eight weeks to establish itself as a credible competitor in the oral GLP-1 market. [Details below.]
Strategic Themes
1. The Wegovy Pill Beat Proves the Oral GLP-1 Market Is Bigger Than Anyone Modeled
A near-100% revenue beat does not happen because the product performed marginally better than expected. It happens because the market systematically underestimated the size and speed of patient demand for an oral obesity therapy. The 2 million cumulative prescriptions and 200,000-plus weekly run rate suggest that the oral GLP-1 addressable market is substantially larger than consensus models assumed. That is bullish for both Novo and Lilly—if the market is bigger than projected, there is room for multiple winners even if the competitive gap persists.
2. No Cannibalization Is the Most Important Data Point for Novo Investors
If the pill had pulled patients off the injectable, Novo would be managing a format transition rather than growing the franchise. Doustdar’s “synergetic effect” comment and the 12% growth in injectable Wegovy confirm that the pill is additive. This means Novo’s total Wegovy franchise is now larger than it was before the pill launched, not just differently distributed. The bull case for Novo’s stock recovery is built on this additive dynamic continuing through Q2 and Q3.
3. 65% of New Obesity Prescriptions Gives Novo a Market Share Moat That Is Hard to Breach
Market share of 65% in new prescriptions creates a self-reinforcing competitive advantage. More prescriptions mean more physician familiarity, which drives more prescriptions. More patients on the drug mean more word-of-mouth and referral volume. More telehealth partnerships mean more distribution reach. Foundayo can chip away at this market share over time, but displacing an incumbent with this level of dominance requires a sustained competitive effort measured in quarters, not weeks.
4. The Dose Titration Curve Will Accelerate Revenue Faster Than Prescriptions
Most Q1 Wegovy pill prescriptions were at the 1.5 mg starter dose, which generates lower revenue per prescription than the 25 mg maintenance dose. As the 1.3 million Q1 patients titrate to higher doses over the next two to three quarters, revenue per prescription will increase even if the total number of new prescriptions remains flat. The heavy starter-dose concentration in Q1 is a temporary suppressor of revenue per script that will resolve as patients move through their titration schedules. Q2 and Q3 revenue should accelerate relative to prescription volume as the patient mix shifts toward maintenance doses.
Frequently Asked Questions
How much revenue did the Wegovy pill generate in Q1?
DKK 2.26 billion (approximately $354 million), nearly doubling the consensus estimate of DKK 1.16 billion. The beat was driven by volume: approximately 1.3 million prescriptions in Q1, with weekly scripts exceeding 200,000 by mid-April. Novo called it the “strongest-ever GLP-1 volume launch in the United States.”
Is the Wegovy pill cannibalizing the injectable?
No. CEO Doustdar told CNBC it is “having not cannibalizations, but a synergetic effect.” Wegovy injectable grew 12% year-over-year to DKK 18.2 billion. The pill is predominantly attracting new GLP-1 patients rather than pulling existing injectable users.
How does Novo’s total Q1 revenue compare to Lilly’s?
Novo reported total revenue of DKK 96.8 billion ($15.2 billion), up 32% year-over-year. Lilly reported its best quarter ever in Q1 with significantly higher total revenue, driven by the combined Mounjaro and Zepbound injectable franchise. Novo’s strength is in the oral GLP-1 segment, where the Wegovy pill dramatically outperformed Foundayo’s early launch.
What is Novo’s market share in obesity?
The Wegovy brand accounts for 65% of new U.S. prescriptions in the obesity category, per CEO Doustdar. This encompasses both the injectable and the pill.
How far ahead is Wegovy pill versus Foundayo?
Cumulative Wegovy pill prescriptions exceeded 2 million by mid-April. Foundayo has reached approximately 20,000 patients. Weekly Wegovy pill prescriptions exceeded 200,000 by mid-April versus Foundayo’s 3,707 in its second full week. The gap reflects Novo’s three-month head start, brand extension advantage, and first-mover dynamics. Lilly says the launch will take “quarters, not days” and RBC says Weeks 8 through 12 are the assessment window.
What is zenagamtide (amycretin)?
Novo’s next-generation obesity candidate, a dual GLP-1/amylin agonist. The AMAZE Phase 3 program was initiated during Q1. If Phase 3 data show superior weight loss to semaglutide alone, zenagamtide would give Novo a mechanism-level advantage beyond current GLP-1 competition.
Did Novo raise guidance?
Yes. Adjusted sales and operating profit decline expectations narrowed from 5-to-13% to 4-to-12%, driven by Wegovy pill momentum. If the pill continues to ramp, additional guidance raises are likely.
What happened with Ozempic?
Revenue was DKK 27.8 billion, down 8% year-over-year but above analyst expectations. The decline reflects competitive pressure from Mounjaro in the diabetes market. Novo launched oral Ozempic (the Rybelsus rebrand) in 70,000-plus pharmacies on May 4, which will contribute to Q2 results.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Novo’s Comeback Quarter. We analyze why the Wegovy pill launch changes the competitive math for the entire oral GLP-1 market, what Doustdar’s “synergetic effect” means for the franchise, and how the additive dynamic between pill and injectable creates a growth trajectory that is fundamentally different from the cannibalization scenario investors feared.
Revenue Per Prescription and the Dose Titration Ramp. We model how the starter-dose-heavy Q1 mix will shift toward maintenance doses over Q2 and Q3, how that shift accelerates revenue per prescription, and why the analysts who underestimated Q1 may be underestimating the second half even more.
What Foundayo Needs to Do: The Competitive Framework. We map the price advantage, dosing convenience, ACHIEVE-4 data, and T2D filing against Novo’s brand dominance and first-mover momentum into a framework for what Lilly needs to demonstrate over Weeks 4 through 12 to establish itself as a credible oral GLP-1 competitor.
Plus: Wegovy HD early launch signals, oral Ozempic rebrand monitoring, zenagamtide AMAZE Phase 3 design, ASCO 24-day countdown, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
